Cabaletta Bio Inc stock is traded at $1.09, with a volume of 1,802,209. It is down -2.25% in the last 24 hours and down -23.05% over the past month. Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Previous Close:
$1.11
Open:
$1.09
24h Volume:
1,802,209
Relative Volume:
0.42
Market Cap:
$234.06M
Revenue:
-
Net Income/Loss:
-$175.43M
P/E Ratio:
-
EPS:
-$1.97
Net Cash Flow:
-$143.28M
1W Performance:
-25.17%
1M Performance:
-23.05%
6M Performance:
-67.22%
1Y Performance:
-54.60%
1-Day Range:
$1.08$1.16
1-Week Range:
$1.08$1.52
52-Week Range:
$1.08$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio IncSector
HealthcareIndustry
BiotechnologyPhone
(267) 759-3100Address
2929 ARCH STREET, PHILADELPHIA, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS